What happened with leucovorin autism claims?

FDA walked back leucovorin as an autism treatment claim

Leucovorin has been publicly promoted as a potential treatment for autism by Trump and Robert F. Kennedy Jr., but the FDA’s regulatory position moved to narrow how it can be used.

After the announcement that increased public attention, outpatient prescriptions for the drug rose sharply. However, FDA action later clarified that leucovorin would be approved only for a specific medical indication: folate deficiency. That distinction matters because it limits the drug’s legitimate use to people who have that deficiency, rather than authorizing it as a general autism therapy.

Why this matters

When a drug is marketed or touted for a new condition without broad regulatory authorization, patients and families may seek it quickly—sometimes delaying other evidence-based care. In this case, the FDA’s “walk back” effectively draws a line between a biologically plausible pathway (folate metabolism) and an autism treatment claim that lacks the kind of approvals regulators typically require for that indication.

What to watch next

Whether clinicians choose leucovorin in autism-related care may depend on individual diagnoses, including whether folate deficiency is present, and on medical judgment aligned with labeled uses.

Overall, the episode highlights how quickly policy statements by prominent figures can translate into prescribing behavior, and how FDA approvals and indications determine the safest, most evidence-aligned boundaries for drug use.